Gvoke Side Effects
Generic name: glucagon
Medically reviewed by Drugs.com. Last updated on Sep 9, 2024.
Note: This document provides detailed information about Gvoke Side Effects associated with glucagon. Some dosage forms listed on this page may not apply specifically to the brand name Gvoke.
Applies to glucagon: nasal powder, powder nasal.
Other dosage forms:
Common side effects of Gvoke
Some side effects of glucagon may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.
Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
More common side effects
- bloody nose
- body aches or pain
- chills
- ear congestion
- fever
- loss of voice
- redness of the eyes
- sneezing
- sore throat
- stuffy or runny nose
- watery eyes
Incidence not known
- change or loss of taste
Serious side effects of Gvoke
Along with its needed effects, glucagon (the active ingredient contained in Gvoke) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking glucagon:
Incidence not known
- blurred vision
- cough
- difficulty with swallowing
- dizziness
- fast, pounding, or irregular heartbeat or pulse
- headache
- hives, itching, skin rash
- nervousness
- pounding in the ears
- puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
- slow heartbeat
- tightness in the chest
- trouble breathing
- unusual tiredness or weakness
Get emergency help immediately if any of the following symptoms of overdose occur while taking glucagon:
Symptoms of overdose
- nausea
- vomiting
For healthcare professionals
Applies to glucagon: injectable powder for injection, nasal powder, subcutaneous solution.
General adverse events
The more commonly reported adverse reactions have included nausea, vomiting, and headache; nasal and ocular symptoms including watery eyes and nasal congestion and itching have been reported with nasal administration.[Ref]
Hypersensitivity
- Very rare (less than 0.01%): Anaphylactic reactions
- Frequency not reported: Generalized allergic reactions[Ref]
Nervous system
- Very common (10% or more): Headache (up to 18.3%)
- Frequency not reported: Dysgeusia (nasal), parosmia (nasal)
Metabolic
- Uncommon (0.1% to 1%): Hypoglycemia
- Very rare (less than 0.01%): Hypoglycemia coma
Hypoglycemia/hypoglycemia coma have been reported in patients using this drug as a diagnostic aid, especially among those patients who have fasted.
Ocular
- Frequency not reported: Watery eyes, itchy eyes, redness of eyes
Watery eyes, itchy eyes, and eye redness were reported when adult patients were specifically questioned if these symptoms were present; some increase in symptom severity was reported by 58.8%, 21.6%, 24.8%, respectively. Symptom worsening of watery eyes, itchy eyes, and eye redness were reported by 47.2%, 16.7%, 13.9%, of pediatric patients, respectively.
Gastrointestinal
- Very common (10% or more): Nausea (up to 26.1%), vomiting (up to 15%)
- Rare (less than 0.1%): Abdominal pain
- Frequency not reported: Throat irritation (nasal)[Ref]
Dermatologic
- Frequency not reported: Pruritus
- Postmarketing reports: Necrolytic migratory erythema (with continuous glucagon (the active ingredient contained in Gvoke) infusions)
Cardiovascular
- Very rare (less than 0.01%): Bradycardia, tachycardia, hypotension, hypertension
Respiratory
- Very common (10% or more): Upper respiratory tract irritation (up to 16.7%)
- Frequency not reported: Nasal pruritus (nasal)
Upper respiratory tract irritation including rhinorrhea, nasal discomfort, nasal congestion, cough, and epistaxis were reported in 12.4% of adult patients in pooled studies of IM and nasal glucagon. In pediatric studies, upper respiratory tract irritation including nasal discomfort, nasal congestion, and sneezing were reported in up to 16.7% of patients. When adult patients were questioned specifically if symptoms of nasal congestion, nasal itchiness, runny nose, sneezing, or itchy throat were present and worsened 42.5%, 39.2%, 34.6%, 19.6%, and 12.4% reported some increase in symptom severity, respectively; 41.7%, 27.8%, and 25% of pediatric patients reported some increase in symptom severity of nasal congestion, nasal itchiness, and runny nose, respectively.
Other
- Frequency not reported: Itching of ears
References
1. (2001) "Product Information. GlucaGen (glucagon)." Novo Nordisk Pharmaceuticals Inc
2. Cerner Multum, Inc. "UK Summary of Product Characteristics."
3. Cerner Multum, Inc. "Australian Product Information."
4. (2019) "Product Information. Baqsimi (glucagon)." Lilly, Eli and Company
5. (2001) "Product Information. Glucagon (glucagon)." Lilly, Eli and Company
Frequently asked questions
- How do you use the Gvoke HypoPen?
- What is Gvoke (glucagon) used for and how does it work?
- When should you use glucagon?
- Are glucagon and glycogen the same thing?
- Insulin vs Glucagon - What do they have in common?
- How does the release of glucagon affect blood glucose levels?
- How long does Baqsimi last?
- How much does Baqsimi cost?
- Is Baqsimi covered by Medicare?
More about Gvoke (glucagon)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (1)
- Drug images
- Latest FDA alerts (1)
- Dosage information
- Patient tips
- During pregnancy
- FDA approval history
- Drug class: glucose elevating agents
- Breastfeeding
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Further information
Gvoke side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.